Home > News > Interview with Karen J. Brunke, Ph. D. at Targesome, Inc.
January 20th, 2003
Interview with Karen J. Brunke, Ph. D. at Targesome, Inc.
Targesome Inc., co-founded by Drs. King Li and Mark Bednarski in late 1999, is developing nanoparticles that can be used for drug delivery. Any drug can be attached to the surface of the nanoparticle, resulting in improved therapeutic properties such as efficacy, safety, and increased half-life in the blood for small molecule drugs (thereby allowing less frequent intravenous dosing).
Sopping up proteins with thermosponges: Researchers develop novel nanoparticle platform that proves effective in delivering protein-based drugs October 22nd, 2014
Bipolar Disorder Discovery at the Nano Level: Tiny structures found in brain synapses help scientists better understand disorder October 22nd, 2014
Journal Nanotechnology Progress International (JONPI), 2014, Volume 5, Issue 1, pp 1-24 October 22nd, 2014
TARA Biosystems and Harris & Harris Group Form Company to Improve Safety and Efficacy of New Therapies October 22nd, 2014